Ophthalmology technology company Smartlens announced the closure of a $6.1 million Series A equity financing round led by Ambit Health Ventures. The company will use the funds to gain regulatory clearance for its offering.
Smartlens offers miLens, an electronics-free soft contact lens that allows providers to gather data to monitor diurnal intraocular pressure using microfluidics technology. MiLens indicates risk factors for glaucoma or the worsening of the condition.
Dr Sam Goldberger, co-founder and managing partner of Ambit Health Ventures stated, “This technology is of the utmost importance in comprehending glaucoma and the daily fluctuations in intraocular pressure. Its implementation will enable physicians to enhance glaucoma treatment and mitigate the risk of permanent vision loss.”
Approximately three million Americans suffer from glaucoma, and the disease is the second leading cause of blindness worldwide.
Click here to read the original news story.